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Abstract 
 
Objective: To re-analyze data from recent randomized trials of statins to assess whether 
the benefits and risks of statins are mediated primarily via their LDL-C lowering effects 
or via other mechanisms. 
 
Approach and Results: We adapted Egger regression, a technique frequently used in 
Mendelian randomization studies to detect genetic pleiotropy, to re-analyze the available 
randomized trial (RCT) data of statin therapy.  For cardiovascular endpoints, each 1 
mmol/L change in LDL-C with statin therapy was associated with a hazard ratio (HR) of 
0.77 (95% CI 0.71-0.84) with an intercept that was indistinguishable from zero [intercept 
= -0.032 (p=0.93)], indicating no pleiotropy. For incident diabetes, a 1 mmol/L change in 
LDL-C with statin therapy was associated with a HR 1.07 (95%CI 0.99-1.16) and an 
intercept non-distinguishable from zero, [intercept = -0.015 (p=0.91)], again indicating 
no pleiotropy. 
 
Conclusion: Our re-analysis of the RCT data using Egger regression adds to the existing 
evidence that the cardiovascular benefits of statins and their association with incident 
diabetes are mediated primarily, if not entirely, via their LDL-C lowering properties 
rather than by any pleiotropic effects. 
 
 
 
Abbreviations 
cardiovascular (CV) 
low density lipoprotein (LDL) 
low density lipoprotein cholesterol (LDL-C)  
inverse-variance weights (IVW)  
instrument strength independent of direct effect (InSIDE) 
no measurement error (NOME) 
single nucleotide polymorphism (SNP)
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Statins directly inhibit HMG-CoA reductase, a critical enzyme regulating de 
novo intracellular cholesterol synthesis. This leads to upregulation of hepatic low-density 
lipoprotein (LDL) receptors and lower circulating LDL, which has been presumed to be 
the primary mechanism producing cardiovascular benefit. Despite prior analyses 
suggesting that the cardiovascular benefits of statins are mediated mainly by the 
reduction in low density lipoprotein cholesterol (LDL-C)1, there has been ongoing debate 
as to whether the observed benefits and risks of statins are mediated exclusively via their 
LDL lowering properties or whether other pleiotropic mechanisms come into play2,3,4.  
The findings from the JUPITER trial5 and subsequent meta-analyses,6,7 which 
demonstrated that statins also increase the risk of new onset diabetes by yet undetermined 
mechanisms, as well as the recently completed FOURIER trial,8 , have reignited this 
debate.   
Herein, we present a new approach to address whether the benefits and risks of statins are 
mediated primarily via their LDL-C lowering effects or via other mechanisms. By 
adapting Egger regression, a technique frequently used in Mendelian randomization 
studies to detect genetic pleiotropy, we re-analyze the available randomized trial data of 
statin therapy. 
 
Methods 
 
We performed a literature review of randomized trials of statin therapy for either 
primary or secondary prevention. In our analysis, we only included trials that 
provided data for a per mmol change in LDL for our two main outcomes of interest: 
major cardiovascular events and new onset diabetes. We compared our results to 
the recent meta-analyses by Sattar et al. 7 Silverman et al.9,  and Chou et al.10 to 
review for any missing studies or data. We included all relevant statin trials 
performed for either primary and secondary prevention.  
 
To assess the potential pleiotropic effects of statins we used a modified form of 
Egger regression.  Briefly, Egger regression was initially developed to assess for 
small study effects and publication bias in meta-analyses. This method has been 
recently adapted by Bowden et al for the Mendelian randomization context to assess 
for genetic pleiotropy11.  Herein, we further adapt Egger regression to the RCT 
context, to assess whether studies with small effects in the mediator of interest, in 
this case, change in LDL-C, (plotted on the x-axis) have the expected small effect on 
the outcomes of interest, in this case, reduction in  cardiovascular (CV) outcomes or 
incident diabetes (plotted on y-axis).  Egger regression estimates the y-intercept of 
such a linear plot to evaluate whether the effect of statins is zero when the LDL-C 
lowering effect is zero, which would indicate no pleiotropy.   
 
First, we performed standard linear meta-regression using the log transformed 
outcome measure from the published studies as the dependent variable and the 
mean LDL change with therapy as the independent variable. For each outcome of 
interest (e.g. reduction in CV events or new-onset diabetes), we performed two such 
linear regressions, first using inverse-variance weights (IVW) and forcing the 
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intercept through zero, which assumes no pleiotropy is present, as previously 
performed by Sattar et al.7 and Silverman et al.9 We then repeated the analysis using 
Egger regression with the intercept unconstrained which allows for possible 
pleiotropy. We compared the goodness of fit of the inverse variance weighted 
approach to the Egger regression using the QR statistic described by Bowden et al.12   
A QR statistic of ~ 1 indicates no or minimal evidence of pleiotropy.  A funnel plot for 
each endpoint was also constructed and is available in the online appendix. 
 
Egger regression makes several assumptions.  In this context, the “instrument 
strength independent of direct effect” (InSIDE) assumption requires that any 
pleiotropic effects must be independent of the strength of the LDL-C change from 
statins. Furthermore, analogous to the No Measurement Error (NOME) assumption 
used in MR which assumes that the majority of the variation in the single nucleotide 
polymorphism (SNP)-exposure associations are due to true differences in exposures 
across SNPs as opposed to other sources of variation (i.e. measurement error for a 
given SNP).  In our context, we assume that the variation in LDL-C change across 
studies is explained by true interstudy differences in LDL-C lowering by statins not 
by other sources of variation (i.e. intrastudy variability, in this case, measurement 
error and/or variable individual response to statins within a study).  
 
Results 
  
We included 25 primary and secondary prevention statin trials that provided 
information on cardiovascular endpoints (see supplementary table 1), as well as 12 
statin trials that provided data on incident diabetes. (see supplementary table 2) A 
list of the included trials and the data included in this analysis are available in the 
online appendix. For the cardiovascular endpoints, the log-transformed hazard ratio 
for every 1 mmol/L change in LDL was -0.26, which translates into a hazard ratio of 
0.77 per mmol/L change in LDL-C (95%confidence interval [CI] 0.71-0.84). (Figure 
1) There was no difference in the slope of the intercept line between the IVW and 
Egger regression and the intercept in the Egger regression was not distinguishable 
from zero [intercept = -0.0320 (p=0.932)]. The QR statistic approximated 1 
demonstrating no meaningful improvement to the goodness of fit of the data when 
the Egger approach is used (Table 1) and suggesting no directional pleiotropy.  
 
Table 1: Results of the IVW and MR-Egger regressions for cardiovascular endpoints* 
 
 IVW Egger 
  Estimate (se) p-value Estimate (se) p-value 
Beta -0.26 (0.017) <0.001 -0.26 (0.042) <0.001 
Intercept n/a‡ -0.032 (0.038) P=0.93 
QR 0.999 
IVW = inverse variance weight, se=standard error 
*estimates are reported on the logarithmic scale 
‡ with IV weight, the intercept term is forced through zero and therefore fixed 
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Figure 1: Hazard ratio for CV events per mmol/L change in LDL. 
Shaded area reflects 95% confidence interval of regression line 
 
For the diabetes endpoints, a per mmol change in LDL was associated with log-
transformed risk ratio of 0.070, which translates into a risk ratio of 1.07 (95%CI 
0.99-1.16). Figure 2. Again there was no distinguishable change when the Egger 
regression technique was used. The intercept using Egger regression was not 
statistically different from zero [intercept = -0.015 (p=0.91)]. Again, the QR statistic 
was very close to the null value of 1 and showed no improvement in the goodness of 
fit when using Egger regression (Table 2), which was again consistent with no 
pleiotropy.  
 
Table 2: Results of the IVW and MR-Egger regressions for incident diabetes* 
 
 IVW Egger 
  Estimate (se) p-value Estimate (se) p-value 
Beta 0.070 (0.037) 0.089 0.081 (0.12) 0.51 
Intercept n/a‡ -0.015 (0.13) P=0.91 
QR 0.999 
 
IVW = inverse variance weight, se=standard error 
*estimates are reported on the logarithmic scale 
 6 
‡ with IV weight, the intercept term is forced through zero and therefore fixed 
 
 
Figure 2: Hazard ratio for incident diabetes per mmol/L change in LDL. 
Shaded area reflects 95% confidence interval of regression line 
 
Discussion 
 
Our re-analysis of the available RCTs suggests that statins do not exert any 
observable pleiotropic effects in mediating their benefits of reducing cardiovascular 
outcomes or in their risks of incident diabetes. In fact, the evidence suggests that 
most, if not all, of their effects are mediated through their LDL lowering mechanism. 
Our results using standard inverse variance weighting with a fixed intercept, mirror 
closely the results obtained by Silverman et al.9 in terms of the effects per mmol 
change in LDL for the reduction in CV events. It is more difficult to directly compare 
our results on diabetes to the analysis by Sattar et al. since they reported only a 
graphical representation of their meta-regression and assessed LDL change as a 
percent change rather than as an absolute change. Nevertheless, graphically, our 
results appear similar. In both settings however, we extend these previous analyses 
by demonstrating that the intercepts of the Egger’s regression are not statistically 
different from zero, which is consistent with no directional pleiotropy in mediating 
either of these outcomes. Also, the QR statistic for both settings is very close to unity, 
which suggests that the Egger’s regression provides no improvement on the 
goodness of fit for either outcome and is consistent with a lack of pleiotropy.  
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Although recently used in the context of Mendelian randomization studies, Egger 
regression can also be applied to the current RCT context. Indeed, Egger regression 
was initially conceived to evaluate small study bias in meta-analyses of RCTs.13 In 
MR-Egger regression, the intercept indicates whether estimates from instruments 
with a small effect are skewed towards either positive or negative outcomes, due to 
directional pleiotropy. Whereas Mendelian randomization studies are concerned 
with the small effects of the genetic instrumental variable, here we substitute the 
small effect of the genetic instrument with the small effect of statins on LDL in 
certain studies, i.e. studies in which statins led to a small change in LDL.   
 
Put another way, in studies where the effects of statins on LDL are small, the risks 
and benefits should also be small if no pleiotropy is present. By extending the MR-
Egger approach to the meta-regression context across several statin RCTs, the near 
zero intercept in our analysis is therefore consistent with the lack of any measurable 
pleiotropy from statins. If pleiotropy was operational, larger than expected benefits 
and/or risks would be observed when LDL change was minimal. Our analysis is 
therefore in keeping with the notion that the primary effects of statins are mediated 
nearly entirely via LDL-C.   
 
It is important to highlight that our results do not exclude the potential role of 
downstream secondary effects of directly lowering LDL-C (e.g. lower inflammation 
as a result of directly lowering LDL-C). In our context, directional pleiotropy refers 
to effects of statins that are independent of their effect of LDL-C. Thus our results do 
not imply that statins only affect LDL-C. Indeed statins have been shown to have an 
effect on venous thromboembolic events in JUPITER 14 and may have a role in 
coagulation. 15 A recent genetic analysis has shown that HMGCR inhibition led not 
only to a lowering of LDL-C, but also to increased body weight, waist circumference, 
plasma insulin concentrations and plasma glucose levels.16 These results strongly 
support the notion that several statin effects that may appear pleiotropic, are in fact 
mediated by their primary “on target” effect which is to lower LDL-C by 
upregulating the LDL receptor, and are therefore, entirely consistent with our 
findings.   
 
 Our results are dependent on the instrument strength independent of direct effect 
(InSIDE) assumption, which assumes that any independent pleiotropic effects are 
independent of the strength of the effect on LDL-C.  To put simply, the InSIDE 
assumption holds that a causal effect, in this case between statins and CV outcomes 
or incident diabetes, can still be estimated if pleiotropy is present, as long as the 
magnitude of the pleiotropy is independent of the statin effect on LDL-C. For 
example, if one speculated that statins exerted independent pleiotropic effects via 
their lowering of C-reactive protein (CRP), the InSIDE assumption would hold true if 
the change in CRP mediated by statins was independent of the change in LDL-C. 
Although this assumption cannot be directly tested across all possible pleiotropic 
mechanisms, analyses from the JUPITER trial have shown that the LDL-C and CRP 
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are only weakly correlated and that the InSIDE assumption likely does hold true in 
this setting.17  
 
Our results that statins exert their effects in reducing CV events and in increasing 
the risk of diabetes primarily via a LDL lowering mechanism is in keeping with 
several lines of evidence. Mendelian randomization studies have shown that, per 
unit change in LDL, any genetic mechanism of LDL lowering leads to similar effects 
on outcomes.18,19 In addition, randomized trial evidence demonstrates that lipid 
lowering agents with different mechanisms of action (e.g. statins, ezetimide, and 
PCSK9 inhibitors) all lead to similar reductions in CV outcomes per mmol/L change 
in LDL-C9.  Using Mendelian randomization, similar results have also recently been 
predicted for incident diabetes, with similar risks of diabetes (per unit change in 
LDL-C) observed across several variants in HMGCR and/or PCSK9 genes.19,20,21  
Although the exact mechanism for statin-related diabetes has not been elucidated 
and many theories have been proposed, 22,23 increased uptake of LDL particles due 
to upregulation of pancreatic LDL receptor activity with subsequent tissue injury 
has been hypothesized, and would be consistent with these findings.  
 
Our analysis has some limitations.  First, the Egger regression results are admittedly 
more robust for the cardiovascular endpoints than for the incident diabetes risk. 
This is due to the fact that more trials have available data on cardiovascular 
endpoints than new cases of diabetes. Second, we utilized data on change in LDL-C 
due to the availability of this measure in all relevant RCTs.  Our analysis focused on 
excluding pleiotropic effects beyond LDL lowering not differentiating whether these 
effects are mediated primarily by lowering the cholesterol content or the number of 
LDL particles. We have previously shown that statin benefit is more strongly 
correlated to lowering apoB, as opposed to LDL-C24, and this has been recently 
corroborated using Mendelian randomization.25 Third, it was not possible to 
estimate the I2 statistic, which would have allowed us to test the NOME assumption 
since not all studies reported the variance of the LDL change.  However, given that 
sample sizes of each included study was large and the effect of statins on LDL-C is 
also known to be relatively strong, the NOME assumption is likely reasonable in this 
case. Therefore, based on our results, the evidence is suggestive, if not definitive, 
that that the benefits of statins on CV disease reduction and incident diabetes are 
mediated primarily, if not entirely by their LDL lowering effect.  
 
Conclusion 
 
While there remains some debate regarding statin pleiotropy and off target effects, a 
re-analysis of the available RCT data using the technique of Egger regression 
suggests that the cardiovascular benefits and the risk of diabetes from statins are 
not mediated through pleiotropic effects but rather through their primary LDL 
lowering mechanism of action. 
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Highlights: 
• Our re-analysis of the available RCTs suggests that statins do not exert any 
observable pleiotropic effects in mediating their benefits of reducing 
cardiovascular outcomes.  
• The association between statins and incident diabetes is also not mediated 
by any observable pleiotropic effects. 
• The evidence suggests that most, if not all, of statins’ effects are mediated 
through their LDL lowering mechanism. 
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Supplemental figure 1: Funnel plot of studies for CV endpoint
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Supplemental figure 2: Funnel plot of studies for incident diabetes endpoint 
 
 
 
